Severe AKI in sars-COVID-19 patients from a tertiary hospital in Rhode Island

Background: The clinical features & outcomes of COVID-19 patients who developed severe AKI are still being elucidated Methods: 42 patients with COVID-19 infection who developed KDOGI stage 3 AKI were identified from March 1 to May 15, 2020, at Rhode Island Hospital, a large tertiary teaching hospital Their clinical presentations and outcomes are presented The data in table 1 were presented as mean (± SD), median (IQR), or # (%) Results: The baseline characteristics are outlined in table 1 Among them, 88% were admitted to ICU, 83% were intubated and needed pressor support 71% received renal replacement therapy (RRT)(56% on CVVHDF) The mean duration of RRT and ICU stay were 6 and 14 days, respectively 33 participants received treatment for COVID-19, among them 14 (33%) received Remdesivir(RDV), 6 (14%) received convalescent plasma(CP), 4 (10%) received hydroxychloroquine(HCQ), and 25 (60%) also received azithromycin The mortality rates were 15% in the RDV group, 67% in the CP group, and 75% in the HCQ group The mortality was 67% in those without any treatment At the 60-day follow-up, 11 (26%) were discharged alive, 21 (50%) died Those who died were older (mean age 71 vs 61), having higher Charlson Comorbidity Index (4 7 vs 3 0), more likely to have diabetes (71% vs 61%) and coronary artery disease (38% vs 24%) Conclusions: The mortality rate of SARS-COVID patients who developed severe AKI is high in our cohort Future larger scale studies are needed to elucidate the causes of this high mortality